Most people infected with the SARS-CoV-2 virus recover after the acute illness. However, a significant proportion of infected individuals develop long-lasting symptoms with a wide range of ...

The MarketWatch News Department was not involved in the creation of this content. -- Dr. Thomas L. F. Montgomery Andresen joins from T-Cypher Bio -- Follows breakthrough non-human primate data ...

Undertaking a study of proteins found in the complement system, an important part of the immune system, of patients with long COVID, researchers have identified a blood protein ‘signature’ that may ...

Share on Pinterest A study offers new clues on why long COVID persists in some individuals. krisanapong detraphiphat/Getty Images Despite the debilitating nature of long COVID, there is an absence of ...

Complement Factor H (CFH) is a pivotal regulator of the complement system, integral to maintaining immune homeostasis and protecting host tissues from undue complement‐mediated damage. By inhibiting ...

Our immune system is armed with an array of defenses designed to detect and eliminate harmful threats. One of its most powerful defense mechanisms is the complement system-a group of proteins that ...

Faults in a certain part of the immune system might be at the root of some long covid cases, new research suggests. For many people, covid is an illness that blusters in and out of our lives as cases ...

Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...

Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...

Complement 3 glomerulopathy (C3G) is diagnosed with a combination of a clinical evaluation, blood tests, urine tests, and a renal (kidney) biopsy. The only way to definitively diagnose C3G and its ...

The story of Q32 Bio, a company that develops therapeutics for inflammatory and autoimmune diseases, started two decades ago. That's when V. Michael Holers, MD, a University of Colorado School of ...